Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

@article{Zinzani2017SafetyAT,
  title={Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.},
  author={Pier Luigi Zinzani and Vincent Ribrag and Craig H. Moskowitz and Jean-Marie Michot and John Kuruvilla and Arun Balakumaran and Yayan Zhang and Sabine Chlosta and Margaret A Shipp and Philippe F Armand},
  journal={Blood},
  year={2017},
  volume={130 3},
  pages={
          267-270
        }
}
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort phase 1b trial. At time of data… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models

  • T Freshwater, R de Greef, +9 authors J. Stone
  • Poster presented at: International Society of…
  • 2015

Similar Papers

Loading similar papers…